- Trade Name: Zejula (Tesaro)
- Indications: Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
- Class: Poly (ADP-ribose) polymerase (PARP) inhibitor
- Half-life: 36 hours
- FDA Approval Date: 03/27/2017
- Clinically important, potentially hazardous interactions with:
None known - Pregnancy: Can cause fetal harm
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
